Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Ono Pharmaceutical Co Ltd (OPHLY)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.84 +0.05    +1.04%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
4.84
-0.00
-0.00%
15:59:37 - Delayed Data
Type:  Equity
Market:  United States
  • Volume: 118,632
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 4.80 - 4.86
Ono Pharmaceutical Co 4.84 +0.05 +1.04%

OPHLY Balance Sheet

 
Featured here, the Balance Sheet for Ono Pharmaceutical Co Ltd, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 4 period ending dates (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Period Ending: 2023
31/12
2023
30/09
2023
30/06
2023
31/03
Total Current Assets 354272 355271 326145 345101
Cash and Short Term Investments 135556 141133 128794 164289
Cash - - - -
Cash & Equivalents 102247 107704 60433 96135
Short Term Investments 33309 33429 68361 68154
Total Receivables, Net 150497 141668 123518 114396
Accounts Receivables - Trade, Net 150497 141668 123518 114396
Total Inventory 46416 48588 50390 44814
Prepaid Expenses - - - 10465
Other Current Assets, Total 21803 23882 23443 11137
Total Assets 891725 895918 871878 882437
Property/Plant/Equipment, Total - Net 104778 105917 107466 108420
Property/Plant/Equipment, Total - Gross - - - -
Accumulated Depreciation, Total - - - -
Goodwill, Net - - - -
Intangibles, Net 58987 60399 67518 69134
Long Term Investments 338825 339326 336873 324178
Note Receivable - Long Term - - - -
Other Long Term Assets, Total - -1 1 -
Other Assets, Total -14106 -763 52551 45313
Total Current Liabilities 89708 101023 91513 122929
Accounts Payable 53112 52973 51898 66794
Payable/Accrued - - - -
Accrued Expenses - - - 11726
Notes Payable/Short Term Debt - - - -
Current Port. of LT Debt/Capital Leases 2266 2338 2433 2490
Other Current liabilities, Total 34330 45712 37182 41919
Total Liabilities 101045 112630 103430 134624
Total Long Term Debt 6320 6636 6954 6678
Long Term Debt - - - -
Capital Lease Obligations 6320 6636 6954 6678
Deferred Income Tax 1004 1016 1005 983
Minority Interest 6023 5998 5961 5944
Other Liabilities, Total -2010 -2043 -2003 -1910
Total Equity 790680 783288 768448 747813
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 17358 17358 17358 17358
Additional Paid-In Capital 17113 17102 17092 17080
Retained Earnings (Accumulated Deficit) 784218 767335 723741 709890
Treasury Stock - Common -91326 -81262 -54161 -54161
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) - - - -
Other Equity, Total 63317 62755 64418 57646
Total Liabilities & Shareholders' Equity 891725 895918 871878 882437
Total Common Shares Outstanding 474.75 478.49 488.33 488.33
Total Preferred Shares Outstanding - - - -
* In Millions of JPY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

OPHLY Comments

Write your thoughts about Ono Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Adam Piergallini
Adam Piergallini May 14, 2020 12:35AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Camostat (oral), TMPRSS2 inhibitor, will prevent / reduce risk of COVID infection.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email